Peter Senter
PhD
Senior Vice President
👥Biography 个人简介
Peter Senter at Seattle Genetics was a pioneer in antibody-drug conjugate (ADC) technology, developing the key linker-payload chemistry used in brentuximab vedotin (anti-CD30 ADC with MMAE payload) — one of the first successful ADCs. His innovations in cleavable linker design, auristatin (MMAE/MMAF) payloads, and drug-to-antibody ratio optimization created the technological foundation that subsequent ADCs have built upon.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Peter Senter 的研究动态
Follow Peter Senter's research updates
留下邮箱，当我们发布与 Peter Senter（Seattle Genetics / Seagen）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment